BR112013009055A2 - antagonista de il-13, uso de um antagonista de il-13, e, método para detectar uma resposta do indivíduo a um tratamento de antagonista de il-13 - Google Patents

antagonista de il-13, uso de um antagonista de il-13, e, método para detectar uma resposta do indivíduo a um tratamento de antagonista de il-13

Info

Publication number
BR112013009055A2
BR112013009055A2 BR112013009055A BR112013009055A BR112013009055A2 BR 112013009055 A2 BR112013009055 A2 BR 112013009055A2 BR 112013009055 A BR112013009055 A BR 112013009055A BR 112013009055 A BR112013009055 A BR 112013009055A BR 112013009055 A2 BR112013009055 A2 BR 112013009055A2
Authority
BR
Brazil
Prior art keywords
antagonist
individual
detecting
response
treatment
Prior art date
Application number
BR112013009055A
Other languages
English (en)
Portuguese (pt)
Inventor
Chris Kell
Lorin Roskos
Nestor Molfino
Raffaella Faggioni
Richard May
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of BR112013009055A2 publication Critical patent/BR112013009055A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/08—Measuring devices for evaluating the respiratory organs
    • A61B5/087—Measuring breath flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
BR112013009055A 2010-10-15 2011-10-14 antagonista de il-13, uso de um antagonista de il-13, e, método para detectar uma resposta do indivíduo a um tratamento de antagonista de il-13 BR112013009055A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39367710P 2010-10-15 2010-10-15
US201161508723P 2011-07-18 2011-07-18
PCT/EP2011/067947 WO2012049278A1 (en) 2010-10-15 2011-10-14 Therapies for improving pulmonary function

Publications (1)

Publication Number Publication Date
BR112013009055A2 true BR112013009055A2 (pt) 2016-07-19

Family

ID=44800047

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013009055A BR112013009055A2 (pt) 2010-10-15 2011-10-14 antagonista de il-13, uso de um antagonista de il-13, e, método para detectar uma resposta do indivíduo a um tratamento de antagonista de il-13

Country Status (15)

Country Link
US (1) US20130281876A1 (https=)
EP (1) EP2627673B1 (https=)
JP (1) JP2013544235A (https=)
CN (1) CN103328506A (https=)
AU (1) AU2011315499A1 (https=)
BR (1) BR112013009055A2 (https=)
CA (1) CA2814431A1 (https=)
DK (1) DK2627673T3 (https=)
ES (1) ES2645368T3 (https=)
HU (1) HUE034005T2 (https=)
MX (1) MX2013004212A (https=)
NO (1) NO2627673T3 (https=)
PL (1) PL2627673T3 (https=)
RU (1) RU2013122123A (https=)
WO (1) WO2012049278A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
CA2937387A1 (en) * 2014-01-27 2015-07-30 Medimmune, Llc Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA2943326A1 (en) 2014-04-11 2015-10-15 Novartis Ag Methods of selectively treating asthma using il-13 antagonists
AU2016205188A1 (en) 2015-01-09 2017-06-22 Medimmune, Llc Assay to detect human DPP-4
CN104605857A (zh) * 2015-02-12 2015-05-13 上海朔茂网络科技有限公司 一种肺功能测量方法
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MX2021010560A (es) 2019-03-06 2021-11-12 Regeneron Pharma Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
JP2023536159A (ja) * 2020-07-31 2023-08-23 ジェネンテック， インコーポレイテッド 炎症性呼吸器疾患の増悪を治療するための方法
CN112341543B (zh) * 2021-01-11 2021-04-23 广东赛尔生物科技有限公司 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用
US20230220089A1 (en) 2021-12-30 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2140660A1 (en) * 1993-06-13 1994-12-22 Uwe R. Juergens Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
GB0004016D0 (en) 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
EP1824886B1 (en) * 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins

Also Published As

Publication number Publication date
CN103328506A (zh) 2013-09-25
ES2645368T3 (es) 2017-12-05
JP2013544235A (ja) 2013-12-12
PL2627673T3 (pl) 2018-01-31
EP2627673A1 (en) 2013-08-21
DK2627673T3 (da) 2017-11-06
EP2627673B1 (en) 2017-07-26
HUE034005T2 (en) 2018-01-29
WO2012049278A1 (en) 2012-04-19
CA2814431A1 (en) 2012-04-19
NO2627673T3 (https=) 2017-12-23
AU2011315499A1 (en) 2013-05-02
US20130281876A1 (en) 2013-10-24
MX2013004212A (es) 2013-09-02
RU2013122123A (ru) 2014-11-20

Similar Documents

Publication Publication Date Title
BR112013009055A2 (pt) antagonista de il-13, uso de um antagonista de il-13, e, método para detectar uma resposta do indivíduo a um tratamento de antagonista de il-13
CY1119286T1 (el) Ανταγωνιστες των wnt και μεθοδοι αγωγης
MX2023004306A (es) Un antagonista de il-4r para usarse en prevenir o tratar la alergia.
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112014000630A2 (pt) anticorpo antagonista ou fragmento do mesmo que se liga a uma ox40 humana, epítopo sobre o domínio extracelular ox40 humano, ácido nucleíco isolado, vetor, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição imunoconjugado, método para tratar um distúrbio mediado por ox40 em um indivíduo, uso de um anticorpo ou fragmento do mesmo, artigo de manufatura, kit e método para classificação in vitro
CL2013002811A1 (es) Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
WO2014031610A8 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
BR112014027155A2 (pt) composições de celúlas t deficientes do re-ceptor de células t
BRPI0818677A2 (pt) Anticorpos que se ligam à il-4 e/ou il-13, composições farmacêuticas compreendendo os referidos anticorpos, bem como usos dos mesmos
WO2012064981A3 (en) Methods to test allergic conditions
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
BR112013024574A2 (pt) polipeptídeo, uso, método de tratamento de indivíduos portadores de doenças e método de tratamento de indivíduos que possuem doenças com um polipeptídeo
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BR112013033671A2 (pt) composições de polipeptídeo de fusão fc livre de arginina e métodos de uso
BR112013029959A2 (pt) uso de anticorpos anti-cgrp e fragmentos de anticorpo para prevenir ou inibir fotofobia ou aversão à luz em sujeitos em necessidade dos mesmos, especialmente os que sofrem de enxaqueca
EP2566492A4 (en) INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY-BASED COMPOSITIONS RELATED TO GLUTAMYL-PROLYL-ARNT-SYNTHASE SYNTHETIC PROTEIN FRAGMENTS
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
IN2014DN07813A (https=)
EP2525822A4 (en) IMMUNREGULATION BY ANTIBODIES TO ILT5 AND ILT5-BINDING ANTIBODY FRAGMENTS
BRPI0906997A2 (pt) Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica
IL221873A (en) Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
FI20135146A7 (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
IN2012DN06588A (https=)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]